Grazyna Liebérman
Impact in
- Oncology top 2%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Internal Medicine top 5%
Papers in
- Oncology 4
- HER2/EGFR in Cancer Research 3
-
- Statistical Methods in Clinical Trials 3
- Co-authors
- William Novotny (2 shared papers)Herbert I. Hurwitz (2 shared papers)Fairooz F. Kabbinavar (1 shared paper)Neal J. Meropol (1 shared paper)Louis Fehrenbacher (1 shared paper)Emily K. Bergsland (1 shared paper)Carla Washington (1 shared paper)Pamela Klein (1 shared paper)
- Journals
- Clinical Breast Cancer (2 papers)Contemporary Clinical Trials (2 papers)Journal of Clinical Oncology (1 paper)Cancer (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Grazyna Liebérman
8 papers receiving 1.7k citations
Grazyna Liebérman's Hit Papers
Peers
Comparison fields: 5 of 82
- Oncology 895
- Internal Medicine 80
- Hepatology 140
- Cancer Research 182
- Pulmonary and Respiratory Medicine 273
Countries citing papers authored by Grazyna Liebérman
This map shows the geographic impact of Grazyna Liebérman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grazyna Liebérman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grazyna Liebérman more than expected).
Fields of papers citing papers by Grazyna Liebérman
This network shows the impact of papers produced by Grazyna Liebérman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grazyna Liebérman. The network helps show where Grazyna Liebérman may publish in the future.
Co-authors
The 25 scholars most cited alongside Grazyna Liebérman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2002 | 1297 |
| 2 | 2005 | 202 | |
| 3 | 2004 | 101 | |
| 4 | 2023 | 43 | |
| 5 | 2005 | 43 | |
| 6 | 2004 | 26 | |
| 7 | 2018 | 11 | |
| 8 | 2013 | 4 | |
| 9 | 2014 | 0 |
About Grazyna Liebérman
Grazyna Liebérman is a scholar working on Oncology, Statistics and Probability, Computational Theory and Mathematics, Immunology and Cardiology and Cardiovascular Medicine, having authored 9 papers that have together received 1.7k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (3 papers), HER2/EGFR in Cancer Research (3 papers), Computational Drug Discovery Methods (2 papers), Biosimilars and Bioanalytical Methods (2 papers), Pharmaceutical Practices and Patient Outcomes (1 paper), Health Systems, Economic Evaluations, Quality of Life (1 paper), Electronic Health Records Systems (1 paper) and Chemotherapy-induced cardiotoxicity and mitigation (1 paper). The work is most often cited by research in Oncology (895 citations), Internal Medicine (80 citations), Hepatology (140 citations), Cancer Research (182 citations) and Pulmonary and Respiratory Medicine (273 citations). Grazyna Liebérman has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include William Novotny, Herbert I. Hurwitz, Fairooz F. Kabbinavar, Neal J. Meropol, Louis Fehrenbacher, Emily K. Bergsland, Carla Washington, Pamela Klein, René Bruno and Ludger Banken. Their work appears in journals such as Clinical Breast Cancer, Contemporary Clinical Trials, Journal of Clinical Oncology, Cancer and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.